Adverum Biotechnologies, Inc.
ADVM
$3.43
$0.103.00%
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -1.45% | -17.00% | -26.82% | -25.51% | -13.04% |
| Gross Profit | 6.27% | 17.00% | 11.74% | 25.51% | 13.04% |
| SG&A Expenses | -29.06% | -69.64% | -10.57% | 23.66% | -19.78% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -12.48% | -36.85% | -20.69% | -10.96% | -15.86% |
| Operating Income | 15.37% | 36.85% | 11.24% | 10.96% | 15.86% |
| Income Before Tax | 17.45% | 41.33% | 14.64% | 24.05% | 18.06% |
| Income Tax Expenses | -- | -- | -- | -6,063.16% | 0.00% |
| Earnings from Continuing Operations | 17.49% | 41.36% | 14.69% | 27.56% | 18.06% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 17.49% | 41.36% | 14.69% | 27.56% | 18.06% |
| EBIT | 15.37% | 36.85% | 11.24% | 10.96% | 15.86% |
| EBITDA | 14.20% | 36.81% | 9.79% | 9.08% | 15.87% |
| EPS Basic | 60.08% | 71.66% | 48.08% | 28.48% | 19.29% |
| Normalized Basic EPS | 60.06% | 71.64% | 48.05% | 12.88% | 19.30% |
| EPS Diluted | 60.08% | 71.66% | 48.08% | 28.48% | 19.29% |
| Normalized Diluted EPS | 60.06% | 71.64% | 48.05% | 12.88% | 19.30% |
| Average Basic Shares Outstanding | 106.69% | 106.93% | 64.30% | 1.29% | 1.53% |
| Average Diluted Shares Outstanding | 106.69% | 106.93% | 64.30% | 1.29% | 1.53% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
